Christopher W. Ryan

Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

Charles D. Blanke, Cathryn Rankin, George D. Demetri et al. · Journal of Clinical Oncology · 2008 · 1.1K citations

Medicine, Oncology, Pharmacotherapy +13

Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group

Michael C. Heinrich, Kouros Owzar, Christopher L. Corless et al. · Journal of Clinical Oncology · 2008 · 653 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial

William D. Tap, Hans Gelderblom, Emanuela Palmerini et al. · The Lancet · 2019 · 474 citations · Full text

Medicine, Oncology, Pharmacology +5

Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial

Andrew J. Armstrong, Susan Halabi, Tim Eisen et al. · The Lancet Oncology · 2016 · 424 citations

Medicine, Oncology, Cancer Pharmacology +13

A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors

Sandip Pravin Patel, Megan Othus, Young Kwang Chae et al. · Clinical Cancer Research · 2020 · 326 citations · Full text

Medicine, Oncology, Pharmacotherapy +17